Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The data overwhelmingly shows net cardiovascular benefit
Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs
JAMA Netw Open 2024;7:e2350050.ArticlePubMedPMC 111
The constant C is chosen so that the second term equals one in the normal steady state (see below)
Jung, E., Kim, J., Ho Kim, S., Kim, S
